The Role of Mitochondrial Dysfunction in CKD-Related Vascular Calcification: From Mechanisms to Therapeutics.
慢性腎病相關血管鈣化中線粒體功能障礙的角色:從機制到治療。
Kidney Int Rep 2024-09-18
Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab.
全球 aHUS 登記分析:患者從 Eculizumab 轉換至 Ravulizumab 的情況。
Kidney Int Rep 2024-09-18
A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD.
一項隨機對照試驗比較自動腹膜透析與血液透析在末期腎病(ESRD)中緊急啟動透析的效果。
Kidney Int Rep 2024-09-18
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
評估 Felzartamab 在抗磷脂酶 A2 受體自體抗體陽性原發性膜性腎病中的安全性和有效性的 1b/2a 階段研究。
Kidney Int Rep 2024-09-18
Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations.
心血管-腎臟-代謝綜合症中心血管、腎臟及代謝疾病的結合,及新的風險預測方程式。
Kidney Int Rep 2024-09-18
Corrigendum to "WCN24-813 MANAGEMENT OF ACUTE FLUID OVERLOAD IN HEART FAILURE PATIENTS WITH CKD USING HOME DELIVERED SUBCUTANEOUS FUROSEMIDE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S251-S252].
對於「WCN24-813 心衰竭合併慢性腎病患者急性液體過載的管理:使用居家配送的皮下注射 Furosemide」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,頁S251-S252]。
Kidney Int Rep 2024-09-18
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容,或是其他相關的問題,請提供更多細節!
相關文章PubMedDOI